Clinical trials: Primary Headache Disorders
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
- Trial name
- NCT03716505
- Testing
- gammaCore Sapphire active
- Where
- 30 sites in United States
- Volunteers
- 231 people
- Sponsor
- ElectroCore INC
Primary Headache Disorders
A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil
This study is an observational study with the primary objective to assess the safety and tolerability of Ausanil in the treatment of primary headache disorders.
- Trial name
- NCT02392273
- Testing
- Ausanil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VR1 Corporation
Migraine Headache
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
A Phase I clinical trial to compare the bioavailability of dihydroergotamine mesylate (DHE) following a single dose administration of INP104 (DHE administered by I123 Precision Olfactory Delivery (POD) Device Nasal Spray) to that…
- Trial name
- NCT03401346
- Testing
- INP104, Dihydroergotamine Mesylate (DHE), Migranal Nasal Spray
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Episodic Cluster Headache, Chronic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL…
- Trial name
- NCT02797951
- Testing
- Galcanezumab
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Migraine
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- UBRO PEDS OLE (NCT05127954)
- Testing
- Ubrogepant
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Acute Migraine
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine
- Trial name
- NCT01973205
- Testing
- Acetaminophen 250 mg and Aspirin 250 mg
- Where
- 19 sites in United States
- Volunteers
- 900 people
- Sponsor
- Novartis
Cluster Headache, Episodic
Eptinezumab in Participants With Episodic Cluster Headache
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
- Trial name
- ALLEVIATE (NCT04688775)
- Testing
- Eptinezumab
- Where
- 120 sites in United States, Belgium and 17 more
- Volunteers
- 231 people
- Sponsor
- H. Lundbeck A/S
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment of migraine.
- Trial name
- Copérnico (NCT01726920)
- Testing
- naratriptan + naproxen, naratriptan, naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine
Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers
the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal sublingual tablet versus commercial Imitrex® sumatriptan…
- Trial name
- NCT02954276
- Testing
- Omexa Sublingual Sumatriptan tablet, Imitrex Oral Product
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Targia Pharmaceuticals Ltd.
Chronic Cluster Headache
Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
The purpose of the proposed clinical study is to evaluate the use of an implanted Neurostimulator to provide Sphenopalatine Ganglion (SPG) stimulation for the management of the pain associated with cluster headaches.
- Trial name
- NCT01255813
- Testing
- Stimulation (Sub-perception), Stimulation (Full), Control
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 43 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine With Aura
Study of NXN 188 for the Treatment of Migraine With Aura
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
- Trial name
- NCT00920686
- Testing
- NXN-188, sumatriptan succinate
- Where
- 16 sites in United States
- Volunteers
- 239 people
- Sponsor
- NeurAxon Inc.
Migraine Headache, Migraine
Neuro-Complex & Multi Supplements for Migraine Prevention
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi…
- Conditions
- Migraine Headache, Migraine, Migraine in Adults
- Trial name
- NeuroCare (NCT07015411)
- Testing
- Neuro-Complex and Multi
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Benfida, a department of Handi-Move
Migraine
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug…
- Trial name
- NCT05064371
- Testing
- Eptinezumab
- Where
- 17 sites in Japan
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).
- Trial name
- NCT04458857
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Chronic Migraine (CM), or 15 or more migraine headaches per month, is common in tertiary headache care and is associated with a number of deleterious outcomes, especially higher disability and poorer quality of life, relative to…
- Trial name
- NCT01435941
- Testing
- Non-steroidal anti-inflammatory drug (NSAID), Triptan
- Volunteers
- 11,249 people
- Sponsor
- GlaxoSmithKline
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines.
- Trial name
- NCT01953341
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.
- Trial name
- NCT07594769
- Testing
- ODT2 Test formulation, ODT Reference formulation
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer